---
schema_version: "secwatch.filing_event.v1"
accession: "0001023024-25-000002"
form_type: "8-K"
ticker: "ANIP"
cik: "0001023024"
company_name: "ANI PHARMACEUTICALS INC"
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T02:37:29.408027+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ANI Pharma prelim Q4/FY24 Cortrophin Gel rev $197.8-198.4M; FY25 rev guidance $739-759M

## Summary
- Cortrophin Gel net rev Q4: $59.2-59.8M; FY24: $197.8-198.4M.
- ILUVIEN/YUTIQ net rev Q4: $26.6-27.2M; post-acquisition period (Sep 16-Dec 31): $30.4-31.0M.
- FY24 total rev, adjusted EBITDA, adjusted EPS expected at or above guidance issued Nov 8, 2024.
- FY25 outlook: total rev $739-759M (24-27% growth vs FY24 midpoint); adj EBITDA $182-192M.
- Full FY24 and detailed FY25 guidance to be reported in late Feb 2025 earnings call.

## SEC filing metadata
- accession: 0001023024-25-000002
- form_type: 8-K
- ticker: ANIP
- cik: 0001023024
- company_name: ANI PHARMACEUTICALS INC
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1023024/000102302425000002/0001023024-25-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1023024/000102302425000002/ani-20250113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001023024-25-000002
- JSON: https://secwatch.observer/filing/0001023024-25-000002.json
- Plain text: https://secwatch.observer/filing/0001023024-25-000002.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.